SCHEMBL3879149

SCHEMBL3879149

CN(C)C(=O)c1ccc(N2CCC(c3nc4c(s3)CCN(C3CCC3)CC4)CC2)cn1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 9/20 0.43
CDK4 P11802 5/20 0.35
CDK2 P24941 3/20 0.35
CDK1 P06493 2/20 0.35
CCND1 P24385 2/20 0.34
GAK O14976 1/20 0.34
CCNT1 O60563 1/20 0.34
CCNA2 P20248 1/20 0.34
FECH P22830 1/20 0.34
CCND3 P30281 1/20 0.34
CDK9 P50750 1/20 0.34
CDK6 Q00534 1/20 0.34
CDK16 Q00536 1/20 0.34
MAP3K1 Q13233 1/20 0.34
CAMK2G Q13555 1/20 0.34
CAMK2D Q13557 1/20 0.34
Q6ZSR9 Q6ZSR9 1/20 0.34
PRKD2 Q9BZL6 1/20 0.34
SIK2 Q9H0K1 1/20 0.34
HSD11B1 P28845 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3879394 0.89 HRH3 (0.44) HRH3PIK3CG
SCHEMBL3880490 0.88 HRH3 (0.55) HRH3
SCHEMBL3882084 0.88 HRH3 (0.47) HRH3
SCHEMBL3879154 0.85 PIK3CG (0.34) HRH3CDK2CDK1PIK3CG
SCHEMBL3881397 0.84 HRH3 (0.40) HRH3KDM2B
SCHEMBL3878465 0.82 HRH3 (0.41) HRH3
SCHEMBL3879396 0.81 HRH3 (0.39) HRH3PIK3CG
SCHEMBL3879080 0.80 HRH3 (0.40) HRH3KDM2B
SCHEMBL3880697 0.79 HRH3 (0.39) HRH3CDK2CDK1KDM2B
SCHEMBL5211397 0.76 HRH3 (0.57) HRH3CDK2CDK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1858900-B1 FUSED THIAZOLE DERIVATIVES HAVING AFFINITY FOR THE HISTAMINE H3 RECEPTOR GLAXO GROUP LTD (GB) 2009-01-07 EP claimed
US-20080161289-A1 Fused Thiazole Derivatives Having Affinity for the Histamine H3 Receptor GLAXO GROUP LIMITED 2008-07-03 US claimed
EP-1858900-B1 FUSED THIAZOLE DERIVATIVES HAVING AFFINITY FOR THE HISTAMINE H3 RECEPTOR GLAXO GROUP LTD (GB) 2009-01-07 EP disclosed
US-20080161289-A1 Fused Thiazole Derivatives Having Affinity for the Histamine H3 Receptor GLAXO GROUP LIMITED 2008-07-03 US disclosed
US-20080161289-A1 Fused Thiazole Derivatives Having Affinity for the Histamine H3 Receptor GLAXO GROUP LIMITED 2008-07-03 US disclosed
US-20080161289-A1 Fused Thiazole Derivatives Having Affinity for the Histamine H3 Receptor GLAXO GROUP LIMITED 2008-07-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080161289-A1 Fused Thiazole Derivatives Having Affinity for the Histamine H3 Receptor HRH3, HRH4, HRH2 HRH3 1/4885CDK4 1856/4885CDK2 1141/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.